Aeon global health asserts that Armando Moncada, MD, FCAP appointed as its Chief medical officer of its Anatomy Pathology business line ushering in on board 20 years of expertise and experience in the sector of pathology along with expertise in other fields like gynecologic, breast, and head and neck pathology and cytopathology as well as in molecular pathology and oropharyngeal and cervical cancer genomics.
Sonny Roshan, Chairman and CEO of Aeon Global Health stated “He has built an impressive reputation for his work in actionable molecular and genetic information related to an individual’s risk for developing cancer. We are confident that this will serve Aeon well as we continue to build a world-class medical information company.”
Dr. Moncada is a Board Certified pathologist by the American Board of Pathology and served as the Chief Medical Officer (CMO) of PCG Molecular, LLC along with being an active member of the following professional organizations: American Medical Association, College of American Pathologists, American Society for Clinical Pathology, American College of Physician Executives, and Association for Molecular Pathology.
Aeon Global Health has also decided to acquire certain intellectual property assets from PCG Molecular, LLC, a genetics and molecular informatics company that has developed proprietary testing for screening for oropharyngeal carcinoma and related infectious diseases. Dr. Moncada is the controlling officer of PCG Molecular.